

1 **RanDeL-seq: A high-throughput method to map viral cis- and trans-acting**
2 **elements**

3
4 Timothy Notton^{1,2,§}, Joshua J. Glazier¹, Victoria R. Saykally¹, Cassandra E. Thompson¹, Leor S.
5 Weinberger^{*,1,3}

6
7 ¹Gladstone Center for Cell Circuitry, Gladstone Institutes, San Francisco, CA, USA

8 ²University of California, Berkeley - University of California, San Francisco Joint Graduate
9 Group in Bioengineering

10 ³Dept. of Biochemistry and Biophysics, University of California, San Francisco, CA, USA

11
12 Running Head: High-throughput screening of viral cis/trans elements

13
14 *Correspondence Address: LSW: leor.weinberger@gladstone.ucsf.edu

15 [§]Current Address: Autonomous Therapeutics, Inc., New York, NY, USA

16

17

18 **Abstract**

19 It has long been known that noncoding genomic regions can be obligate *cis* elements acted upon
20 *in trans* by gene products. In viruses, *cis* elements regulate gene expression, encapsidation, and
21 other maturation processes but mapping these elements relies on targeted iterative deletion or
22 laborious prospecting for rare, spontaneously occurring mutants. Here, we introduce a method to
23 comprehensively map viral *cis* and *trans* elements at single-nucleotide resolution by high-
24 throughput random deletion. Variable-size deletions are randomly generated by transposon
25 integration, excision, and exonuclease chewback, and then barcoded for tracking via sequencing
26 (i.e., **R**andom-**D**eletion **L**ibrary **s**equencing, RanDeL-seq). Using RanDeL-seq, we generated and
27 screened >23,000 HIV-1 variants to generate a single-base resolution map of HIV-1's *cis* and *trans*
28 elements. The resulting landscape recapitulated HIV-1's known *cis*-acting elements (i.e., LTR, Ψ ,
29 and RRE) and surprisingly indicated that HIV-1's central DNA flap (i.e., central polypurine tract,
30 cPPT to central termination sequence, CTS) is as critical as the LTR, Ψ , and RRE for long-term
31 passage. Strikingly, RanDeL-seq identified a previously unreported ~300bp region downstream of
32 RRE extending to splice acceptor 7 that is equally critical for sustained viral passage. RanDeL-seq
33 was also used to construct and screen a library of >90,000 variants of Zika virus (ZIKV).
34 Unexpectedly, RanDeL-seq indicated that ZIKV's *cis*-acting regions are larger than the UTR
35 termini, encompassing a large fraction of the non-structural genes. Collectively, RanDeL-seq
36 provides a versatile framework for generating viral deletion mutants enabling discovery of
37 replication mechanisms and development of novel antiviral therapeutics, particularly for emerging
38 viral infections.

39

40

41 **Importance**

42 Recent studies have renewed interest in developing novel antiviral therapeutics and vaccines based
43 on defective interfering particles (DIPs)—a subset of viral deletion mutant that conditionally
44 replicate. Identifying and engineering DIPs requires that viral *cis*- and *trans*-acting elements be
45 accurately mapped. Here we introduce a high-throughput method (Random Deletion Library
46 sequencing, RanDeL-seq) to comprehensively map *cis*- and *trans*-acting elements within a viral
47 genome. RanDeL-seq identified essential *cis* elements in HIV, including the obligate nature of the
48 once-controversial viral central poly-purine tract (cPPT) and identified a new *cis* region proximal
49 to the Rev responsive element (RRE). RanDeL-seq also identified regions of Zika virus required
50 for replication and packaging. RanDeL-seq is a versatile and comprehensive technique to rapidly
51 map *cis* and *trans* regions of a genome.

52

53 **Introduction**

54 A generalized feature of genome structure is the presence and interplay of *cis*-acting and *trans*-
55 acting elements (1). In viruses, trans-acting elements (TAEs) comprise viral gene-expression
56 products such as proteins and RNAs that drive molecular processes involved in viral replication,
57 maturation, and release (2). Viral cis-acting elements (CAEs) are sequences within the viral
58 genome that are acted upon by TAEs, or that interact with other regions of the viral genome, to
59 enable TAE-mediated genome replication, encapsidation, and other processes essential to viral
60 maturation (3, 4). Across viral species, CAEs are conserved at the 5' and 3' ends, forming
61 secondary structures such as stem loops and higher order structures that aid genomic stability or
62 increase interaction with TAEs (5). Function can be often inferred from location, with 5' CAEs
63 correlating to replication and initiation of translation, and 3' CAEs to nuclear export, RNA
64 processing and RNA stability (6). CAEs can also be found within gene-coding regions and function
65 in ribosomal frameshifting, RNA replication, and specifying the RNA for encapsidation (5).

66
67 Mapping and characterization of viral CAEs has elucidated critical molecular mechanisms in the
68 lifecycles of a number of viruses (3, 7). For example, packaging signals, frameshifting signals, and
69 internal ribosome entry sites (IRES) are critical CAEs and represent putative inhibition targets (8).
70 Despite the challenges associated with disruption of structural elements, the high conservation rate
71 of these sequences makes them attractive antiviral targets (4, 9).

72
73 One area where mapping of viral CAE and TAEs is clearly important is in rational design of live-
74 attenuated vaccines (LAVs) (10, 11); LAV-candidates lacking CAEs have reduced replicative
75 fitness. Thus, CAE retention may be required for efficient replication and immunogenicity of the

76 LAV candidate. Alternatively, it is possible that deletion of CAEs could enable calibration of viral
77 replication for attenuation. Knowledge of conserved features is also important for viruses subject
78 to high recombination or mutation rates (12), and a rapidly implementable, attenuation platform
79 would clearly be beneficial (13). Additionally, knowledge of conserved viral regions aids the
80 development of complementary attenuation strategies, such as microRNAs (14).

81
82 Mapping viral CAEs and TAEs may also aid development of novel classes of antivirals that act
83 via genetic interference (15) and are proposed to have high barriers to the evolution of viral
84 resistance. One class of proposed antivirals are Therapeutic Interfering Particles (TIPs), engineered
85 molecular parasites of viruses based upon Defective Interfering Particles (DIPs). DIPs are sub-
86 genomic deletion variants of viruses that do not self-replicate but conditionally mobilize in
87 presence of wild-type virus and can interfere with wild-type replication (16-23). TIPs are enhanced
88 DIPs proposed to retain all CAEs and interfere with wild-type replication by stoichiometric
89 competition for TAEs, such as packaging proteins, within the infected cell. Enhanced replication
90 of DIP/TIPs in turn reduces the wild-type viral load. Current candidates (24-26) are generated by
91 traditional methods of high-multiplicity of infection (MOI) serial passage or UV-inactivation. A
92 high-throughput, rational genetics approach to development DIPs and TIPs would aid screening
93 and identification of safe and effective candidates.

94
95 Despite the benefits of mapping viral CAE and TAEs, methods to do so, especially for CAEs, tend
96 to be laborious and/or highly technical, and traditionally focused on protein-coding sequences,
97 rather than on regulatory sequences (27, 28). Highly technical methods include multicolor long-
98 term single-cell imaging (29), CRISPR/Cas9 deletion tiling (27, 30), chemical probing approaches

99 (31), targeted RNA mutagenesis and functional binding assays (32, 33), and bioinformatics (6,
100 34). Most methods, however, still rely on viral defective interfering (DI) RNAs, deducing critical
101 genomic regions by serial passage. CAEs are in turn mapped by analyzing deletion variant
102 sequences that persist or produce infectious virions. DI RNA studies reveal critical genomic
103 regions that can be investigated further with reverse genetics systems such as site-directed
104 mutagenesis (35-39) or iterative deletion vectors (40-44).

105
106 These approaches are limited by the ability to examine one element at a time, iterating deletions
107 around one factor, or deleting portions of the viral genome. Not all viruses have naturally occurring
108 DI RNAs, and generating them by serial passage is straightforward, but laborious. Deletion
109 mutants arise at low frequency and remain rare unless a deletion confers increased fitness relative
110 to the wild-type virus. A number of methods to generate defined mutants and random deletions at
111 an appreciable frequency using reverse genetic systems exist, such as creating short random
112 deletions with endonucleases (45) or using synthetic DNA and site-specific recombinases (46) for
113 larger deletions. Other methods insert transposon cassettes into viral genomes to disrupt CAE and
114 TAEs by separating protein domains or introducing missense and nonsense mutations (47-50).
115 These methods do not generate deletion mutants at scale, and all have certain drawbacks, whether
116 it be non-random mutation/deletion, viral insertion scarring, reliance on previously characterized
117 DIPs, inability to generate and track full-length viral mutants, or the price, labor, and versatility of
118 the method.

119
120 In this study, we present a versatile framework for generating random deletion libraries of viral
121 species in high throughput and mapping viral CAE and TAEs without laborious and iterative

122 deletion. Through *in vitro* transposition, dual exonuclease chewback, and barcode ligation,
123 RanDeL-seq (**R**andom **D**eletion **L**ibrary **s**equencing) generates diverse randomized libraries of
124 barcoded viral deletion variants ($>10^5$ unique mutants) at modest expense in fewer than 5 days. As
125 proof of concept, we demonstrate the construction and screening of tagged libraries of $>23,000$
126 deletion mutants of HIV-1 and $>90,000$ deletion mutants of Zika virus (ZIKV). Repeated *in vitro*
127 passage and deep sequencing of the pooled viral mutants comprehensively mapped HIV-1 and
128 ZIKV at single-base resolution, identifying established viral CAEs and revealing the importance
129 of other viral regions for sustained viral replication in cells, such as the cPPT and splice acceptor
130 7 (SA-7) in HIV-1 and non-structural proteins in ZIKV.

131

132 **A Method to Generate a Random Deletion Library (RanDeL) – HIV-1 case study**

133 To map viral cis- and trans-acting elements, we developed RanDeL-seq, a technique to efficiently
134 generate and screen **R**andom **D**eletion **L**ibraries of a viral species in high-throughput. The method
135 (Fig 1A) involves deletion via *in vitro* transposition, transposon excision, dual exonuclease
136 chewback, and re-ligation with molecular barcodes able to be mapped by deep sequencing. Viral
137 mutants could be followed over time by their unique barcodes at a resolution not attainable by
138 standard sequencing of pooled viral nucleic acids (51).

139

140 To start, we designed a synthetic transposon cassette, TN5MK, (Fig. 1B) compatible with the well-
141 characterized hyperactive Tn5 transposase (52-54). Transposons contained an antibiotic-resistance
142 marker to select for plasmids harboring a successful transposon insertion. Transposon integration
143 into the target plasmid introduces unique restriction sites for uncommon meganucleases, I-SceI

144 and I-CeuI, with long recognition sites (Fig S1A). The length of the recognition site confers
145 specificity and is advantageous for use without modification in many systems.

146

147 The conventional HIV-1 molecular clone pNL4-3 (Fig. 1C), was the substrate for this library
148 construction. The system allows control over the size of deletions and can tag each member of the
149 diverse deletion library with a molecular barcode to facilitate deep sequencing analysis. The
150 molecular biology details of RanDeL-seq are in Figure 1D. Each step was validated after
151 completion, with a comprehensive check on the finished libraries.

152

153 First, we performed *in vitro* transposition to randomly insert TN5MK into pNL4-3 at a ratio of one
154 transposon per viral plasmid. The insertion libraries were treated with both encoded restriction
155 enzymes, generating the expected ~ 1.4 kb excised transposons in addition to linearized pNL4-3
156 plasmid backbone (Fig. 1E). Deep sequencing of the pNL4-3 insertion library enabled mapping of
157 insertion sites across the genome (Fig. 1F), showing TN5MK integrated broadly throughout the
158 pNL4-3 plasmid, with a high frequency and density of at least one transposon integrated every 100
159 bp. In the plasmid backbone, two integration gaps emerged: one in origin of replication, ori, and
160 the other in the resistance marker, as both are required for propagation of the plasmid in *E. coli*.

161

162 After creating a polyclonal population of transposon-inserted circular target DNAs, insertions were
163 excised by meganuclease treatment. DNA chewback with a trio of proteins (T4 DNA polymerase,
164 RecJF, and SSB) efficiently created truncations in a common buffer system (Fig S1B). Chewback
165 rate was determined by a dsDNA fluorometric method, using a 4 kb template DNA. As the ends
166 were progressively shortened by chewback, the fluorescence signal of a dsDNA-specific dye

167 (PicoGreen) decreased proportionally. The measured double-end chewback rate, as determined by
168 linear regression, was approximately 50–60 bp/min (Fig 1G). Sub-libraries of mutants with diverse
169 deletion sizes were then created by varying the enzymatic incubation time. Finally, linearized sub-
170 libraries were pooled, end-repaired, dA-tailed, dephosphorylated, and recircularized by ligation to
171 a 3' dT-tailed 60 bp barcode cassette. The barcode cassette was designed to have a 20-bp random
172 barcode flanked by 20-bp primer-binding sites, taken from Tobacco Mosaic Virus to limit
173 sequence complementarity with human viruses (Fig S2). Each successful ligation resulted in a
174 deletion mutant tagged with a unique barcode cassette.

175
176 We validated the final library via several different methods (Fig. 1H). First, to test if the transposon
177 insertion was fully excised, libraries were restriction enzyme digested by I-CeuI. The completed
178 library (Lane 7) was insensitive, compared to a digested insertion library (Lane 3), confirming
179 TN5MK excision and removal in chewback. Second, an untreated deletion library had a range of
180 sub-genomic sizes (Lane 5) in comparison to an untreated insertion library (Lane 1), confirming
181 that chewback created deletions of various sizes. Lastly, to test successful recircularization with
182 the barcode cassette, the digested insertion and deletion libraries were treated with RecBCD, an
183 enzyme that degrades linear dsDNA. We hypothesized that treated insertion libraries and deletion
184 libraries that maintained I-CeuI cut sites or were not properly ligated to barcode cassettes will be
185 completely degraded. Post-treatment the deletion library was unchanged, as the digested plasmids
186 are uncut and circular from ligation to the barcode cassette (Lanes 6 & 8). On the other hand,
187 treatment of insertion libraries degraded all plasmid (Lane 4).

188

189 **Framework for efficiently sequencing barcoded HIV-1 RanDeL**

190 Post validation of the tagged RanDeL, we developed a framework for genotyping barcoded
191 mutants in order to track each unique deletion mutant in culture and calculate a viral deletion depth
192 profile. RanDeL-seq relies on the initial whole genome sequencing of the deletion library to
193 construct a look up table that links each unique barcode sequence to a specific deletion locus. This
194 initial genotyping step allows for efficient sequencing downstream, as only barcode cassettes need
195 to be sequenced downstream to identify which deletion mutants persist in culture.

196

197 The plasmid library was fragmented, deep-sequenced (2 x 125b reads on HiSeq4000) with
198 Illumina™ paired-end sequencing and analyzed with custom python software (rdl-seq). Reads
199 were filtered for the small percentage (2.9%) that contained the full barcode cassette (Table S1).
200 Repeated barcode sequences were grouped together to determine the consensus bases 5' and 3' of
201 that specific barcode cassette (i.e., barcode flanking sequences). Flanking sequences were aligned
202 to the viral reference genome, generating a lookup table of barcodes ($B = b_1, b_2, b_3 \dots b_n$) matched
203 to deletion loci ($D = d_1, d_2, d_3 \dots d_n$). After the initial genotyping of the plasmid random deletion
204 library, deletion variants can be identified by amplifying barcodes cassettes with primers annealing
205 to the common primer-binding sites.

206

207 This sequencing framework determined there were 23,851 unique mutants with a range of deletion
208 sizes (Fig 1I). The library subset had a median deletion size of ~ 1.1 kb, a minimum deletion of 30
209 bp and a maximum deletion size of >6 kb. The skewing of the library (i.e. long tail to high kb),
210 may be due to mechanical shearing of DNA during some of the cleanup steps.

211

212 Next, the deletion-depth profile (location and abundance of deletions) of the pNL4-3 deletion
213 library was calculated (Fig 1J). The plasmid library exhibits deletions across the HIV genome,
214 with a peak in the *env* gene, and a region of zero deletion depth was observed at the plasmid origin
215 of replication (*ori*) and antibiotic resist marker (*bla*). Biases in the deletion depth at this stage
216 corresponds to differences in bacterial growth rate; faster growing bacteria lead to
217 overrepresentation of their harbored plasmid. The signal peptide of *env* and sequences at the N-
218 terminus are known to be toxic to bacteria, therefore bacteria harboring *env* deletions likely have
219 a growth advantage, and bacteria harboring *ori/bla* deletion plasmids are unable to grow in the
220 antibiotic.

221

222 **Serial-passage screening of HIV-1 RanDeL to map viral CAE and TAEs**

223 To functionally characterize the deletion library, we designed a high multiplicity of infection
224 (MOI) passage scheme to select for and map viral CAEs by sequencing the barcodes that persisted
225 through multiple passages together with replication-competent HIV-1. A high MOI ensured that
226 on average, each cell became infected with more than one copy of the wild-type virus to supply
227 trans factors. The diversity of the library was limited to fewer than the number of available cells
228 to maintain strong selective pressure, avoid drift, and ensure that most of the library would be
229 sampled multiple times during infection. In this scheme, the genomic regions that can tolerate
230 deletion (as measured by enrichment of specific barcodes corresponding to that region) correspond
231 to TAEs, while regions that are intolerant of deletion correspond to CAEs. Regions of the genome
232 could also be neutral (i.e., extraneous or ‘junk’ regions) but given the extreme selection pressures
233 that viral genomes face, such neutral regions (non cis, non trans) are expected to be small,
234 especially for RNA viruses.

235

236 Wild-type virus and deletion library pools were packaged by co-transfection of 293T cells with
237 equal masses of the pNL4-3 deletion library and pNL4-3 parental plasmid. Clarified supernatant
238 (0.45 μ m filtered) was concentrated by ultracentrifugation and used to transduce MT-4 cells at
239 high MOI in three parallel biological replicates (designated K, L, and M) for twelve passages (Fig
240 2A). In parallel, three flasks were infected with wild-type HIV-1 only as a negative control for
241 deletion library barcodes. In this high MOI passage scheme (Fig 2B), cultures were infected with
242 concentrated virus, then supplemented with naive MT-4s every 24 hours before being harvested 3
243 days (i.e. 3 passages) later. By supplying naive target cells, the scheme selected for two
244 phenotypes: (a) replication-competent viruses and (b) replication-defective viruses that are
245 efficiently trans-complemented by wild-type virus (i.e., mobilized). Flow cytometry of high MOI
246 conditions showed an initial high percentage of infected cells, followed by an expected drop after
247 the addition of naive MT4s, and then a return to high infected percentage before harvest. (Fig S3).

248

249 **Tracking RanDeL barcodes throughout serial-passage experiments**

250 Viral RNA from cell-free supernatants was analyzed by RT-qPCR to detect barcode sequences
251 and determine which deletion variants persisted passage to passage. Barcodes were detectable in
252 all deletion library samples in the serial-passage, and in none of the control flasks. The ratio of
253 barcodes to total HIV genomes slightly decreased over time from the initial co-transfection of
254 deletion library samples (Fig. 2C). Expression of total HIV genomes was not significantly different
255 between the library and control samples (Fig S4A), indicating no interference from the deletion
256 library.

257

258 Using custom Illumina-prep for barcode sequencing (Fig S5), the prevalence of each deletion
259 variant in the total population of barcoded mutants was tabulated, and the prevalence trajectory
260 throughout the passage computed. Of the 23,851 mappable pNL4-3 deletion mutants, only 4390
261 (18%) were detectable in all three replicate flasks by passage 12—the remaining 19,461 (82%)
262 barcodes were undetectable and presumably were extinct in at least one of the three replicates.
263 Overall there was strong concordance in barcode prevalence between the three replicates (Fig
264 S4B).

265
266 We computed trajectories for the 4390 barcoded deletion variants, calculated the change in
267 prevalence versus passage number (i.e., slope) by linear regression, and classified variants by slope
268 (Fig 2D). Linear regression analysis determined that 1390 (32%) of the 4390 persisting deletion
269 variants increased in prevalence through every passage, indicating that variants harboring these
270 deletions were transmitting better than the average member of the barcoded population (Fig 2E).
271 The remaining 3000 mutants remained steady or decreased in prevalence passage to passage. As
272 barcode levels were relatively constant to total HIV genomes, we hypothesize that these 1390
273 persisting variants are transmissible ($R_0 > 1$) and can be efficiently complemented in *trans* (i.e.,
274 these deleted regions can be compensated for by gene products expressed from wild-type HIV-1)
275 and can spread through the population as fast or faster than wild-type HIV-1.

276

277 **HIV-1 Deletion Landscapes identify CAE and TAEs**

278 Using deep-sequencing counts of barcodes and referencing back to the barcode-to-genotype look-
279 up table, deletion landscapes (a.k.a. deletion-depth profiles) were calculated for the HIV-1 genome
280 at various timepoints in the screen. First, we sequenced barcodes in intracellular poly(A) RNA

281 purified from the 293T cells (Fig. 2F) used to package the deletion library. The 5' end of the HIV-
282 1 genome (spanning the 5' LTR through SL1–SL4) exhibited low deletion depth, while the rest of
283 the genome showed little reduction in barcode coverage. This deletion landscape reflects known
284 CAEs required for efficient HIV-1 transcription in 293T cells.

285

286 Next, barcodes were sequenced from the cell-free supernatant of 293T cells (Fig. 2G), representing
287 deletion variants able to be transcribed, packaged into virions (encapsidated), and released from
288 the cell (egressed). This supernatant deletion landscape differed from intracellular RNA deletion
289 landscape in two key genomic regions: (i) the region of zero deletion depth beginning at the 5'
290 LTR and extending through the start codon of *gag*, which includes the HIV-1 packaging signal
291 (*psi*, Ψ), and (ii) at the 3' end of the genome, the stretch of zero deletion depth that maps to the
292 Rev Responsive Element (RRE)—a region of secondary structure critical for nuclear export of
293 incompletely spliced HIV-1 RNAs (55, 56). These data indicate that the LTR, Ψ , and RRE were
294 the only elements critical for efficient transcription, encapsidation, and egress of HIV-1 from 293T
295 cells; all other regions tolerated some amount of deletion.

296

297 Deletion landscapes were then calculated to profile the changes in the deletion library passage to
298 passage in MT-4 cells. At passage 3 (Fig. 2H), the deletion landscape diverged notably from the
299 293T-intracellular and supernatant profiles in three key ways: (i) a valley of reduced deletion depth
300 appeared, with a minimum centered above the cPPT/CTS, (ii) the region of zero-deletion depth at
301 the 5' end of the genome shifted, encompassing the 5' LTR through the first three hundred bases
302 of *gag*, and (iii) a widening and 3' shift of the deletion-depth valley situated around the RRE

303 occurred. At passage 6 (Fig. 2I), these features had become more pronounced, and each valley had
304 flattened to a deletion depth near zero.

305

306 No significant landscape differences were found between passages 9 and 12, enabling construction
307 of a consensus map (Fig. 2J). Three regions of the HIV-1 genome were tolerant to deletion and
308 able to be complemented efficiently in *trans*. These deletion-tolerant regions were classified as
309 TAEs and are: (i) a region centered at the deletion peak at the center of *pol* (TAE1), (ii) a region
310 in HIV's accessory gene tract (*vif-vpu*) (TAE2), and (iii) a region in the 3' end of *env* (TAE3).

311

312 The final deletion-depth profile contained four regions of low or zero deletion depth, indicating
313 that these genomic are required CAEs. CAE1 is the first 1114 nucleotides of the proviral genome,
314 encompassing known CAEs the 5' LTR, stem loops 1–4, and the first 325 bp of *gag*, which maps
315 to the Gag MA (p17) and Ψ . CAE2 maps directly to the cPPT/CTS. The requirement for HIV
316 cPPT in reverse-transcription and integration has been debated in the past, with the literature
317 supporting (31, 57-61) and questioning (62-65) its role. Here, the data support a critical role for
318 cPPT in sustained HIV-1 replication. CAE3 begins at the RRE and ends precisely at splice acceptor
319 7 (SA-7), which is used for several multiply spliced HIV-1 transcripts, including *vpr*, *tat*, *rev*, *nef*
320 (66), and implicated in viral fitness (56). While the importance of the RRE and SA-7 were known
321 (31, 67, 68), RanDeL-seq showed that the entire 300 bp region from the upstream RRE to the end
322 of SA7 is required for sustained viral replication, and cannot be provided in *trans*. Finally, CAE4
323 spans the PPT, which is necessary for reverse transcription, and the 3' LTR (18).

324

325 **Application of RanDeL-seq to identify Zika Virus CAEs**

326 To determine if this approach has the potential to be more generally applicable across diverse
327 viruses, we performed RanDeL-seq on Zika virus (ZIKV). ZIKV is a flavivirus with a (+)-stranded,
328 ssRNA genome of approximately 11 kb that replicates predominantly in the cytoplasm of infected
329 cells. Libraries were built using two cDNA molecular clones of the conventional 1947 Ugandan
330 strain of ZIKV, MR-766 (69). The first clone, Pol(+) pMR766, encodes the wild-type virus (Fig.
331 3A), whereas the second clone, Pol(-) pMR766, encodes a defective mutant with a substitution in
332 the active site of the essential RNA dependent RNA polymerase NS5. Consequently, pMR766(-)
333 virus is not replication-competent, unless rescued by providing NS5 in trans. pMR766(+) and
334 pMR766(-) insertion libraries were generated with TN5MK. Next, the transposon was excised,
335 enzymatic chewback performed to generate deletions, and the cDNA re-circularized by ligation in
336 the presence of a random barcode cassette. Both short (S) and long (L) duration chewbacks were
337 performed for each insertion library to create small and large average deletion sizes, respectively.
338 Overall, four ZIKV RanDeLs were generated: pMR766(+)S, pMR766(+)L, pMR766(-)S, and
339 pMR766(-)L.

340
341 Each ZIKV RanDeL was validated per methods similar to those used for the HIV-1 library (Fig.
342 3B). Restriction-enzyme analysis with I-SceI and I-CeuI showed transposon excision in both sets
343 (+ and -) of insertion libraries (lanes 7-10). Undigested, completed deletion libraries ran at 2–10kb
344 (lanes 1–4) confirming various sized deletions as a result of chewback incubations. Successful
345 plasmid re-ligation and re-circularization of each deletion library was analyzed by restriction
346 analysis with KpnI, a restriction enzyme with a single unique site in both ZIKV wild-type
347 plasmids. Consistent with successful plasmid re-circularization, KpnI digestion generated single
348 bands (lanes 11-14)—i.e., linearized molecules arising from a cut of a circular plasmid as opposed

349 to two molecules arising from cutting of a non-circularized, linear DNA molecule. These KpnI-
350 digested single bands migrated at sizes larger than the undigested supercoiled libraries KpnI (lanes
351 1-4).

352

353 Whole-plasmid sequencing of the four ZIKV RanDeLs determined the deletion diversity to be
354 between 1,000 and 50,000 mappable deletions per library (Table S1). Short-chewback libraries
355 had less diversity than long-chewback libraries, likely due to some short-chewback reactions
356 failing to chew past the transposon cassette, rendering it impossible to determine the mutation
357 location. The deletion-size distribution of the ZIKV RanDeLs differed from the HIV-1 RanDeLs
358 (Fig. S6) in that ZIKV RanDeL distributions were clearly bimodal, with peaks at small and large
359 deletion sizes. Increasing the length of the chewback shifted the lower peak, but not the upper
360 peak, possibly indicating that clones that lost the ZIKV cDNA insert had a replication advantage
361 in bacteria. Due to the increased diversity and functionality, we focused on the pMR766(+)
362 library.

363

364 The pMR766(+)_L plasmid library showed deletions across the ZIKV genome (Fig. 3C), with a
365 peak at NS1, and a region of zero deletion depth at the flanking region of the genome,
366 corresponding to the plasmid backbone (ori/bla). Given that deletion variants from the
367 pMR766(+)_S, pMR766(-)_L, and pMR766(-)_S libraries did not ultimately passage efficiently in
368 cells, we did not construct deletion landscapes for the libraries from these plasmids. Similar to the
369 HIV plasmid landscape, deletion of these backbone regions compromises the ability of the plasmid
370 to be propagated effectively in bacteria. The peak centered at NS1 reflected increased growth of

371 mutants with deletion in NS1, which is known to have cryptic promoter activity and cause reduced
372 growth in *E. coli* (60, 69, 70).

373

374 As with HIV-1, wild-type ZIKV and RanDeL variants were packaged by co-transfection of 293T
375 cells using equal masses of each ZIKV RanDeL and the wild-type clone. Filtered, concentrated
376 virus-containing supernatant was isolated, pooled, and used to infect Vero cells at high MOI (>16).
377 The viral pool was passaged three times in Vero cells, in parallel to a wildtype-only control
378 infection.

379

380 Viral RNA was analyzed from transfected 293T cells and cell-free supernatant at each passage by
381 RT-qPCR to quantify RanDeL barcodes and total ZIKV genomes. First, we verified that barcoded
382 mutants could be detected intracellularly post-transfection of each individual library (Fig S7A)
383 and each day post-infection (dpi) in passage 1 (Fig. 3D). At 1 dpi, barcodes represented < 0.01%
384 of total Zika genomes and did not increase in percentage by 3 dpi. Total viral genomes (ZIK-C) in
385 RanDeL co-transfected samples were not significantly different from the control infection (Fig
386 S7B), indicating the absence of a detectable interference effect from ZIKV variants, in agreement
387 with the HIV results. However, a significant drop-off in barcode prevalence was observed between
388 intracellular RNA post-transfection and supernatant RNA post-infection, indicating a strong
389 selective pressure (i.e., bottleneck) on RanDeL variants between transcription and egress.

390

391 To identify CAEs, deletion-depth profiles were constructed by Illumina™ sequencing of ZIKV
392 RanDeL barcodes after co-transfection, passage 1, and passage 2. The deletion landscape of
393 intracellular RNA in co-transfected 293T cells was similar to the plasmid profile with a couple

394 notable exceptions (Fig. 3E). First, at the 5' end of the genome, deletions of the internal CMV
395 promoter (bases 1–721) inhibited transcription because the CMV promoter is required for
396 transcription of the ZIKV RNA genome. Second, at the 3' end of the genome, deletions of the HDV
397 ribozyme and poly(A) sequence also inhibited to transcription.

398

399 Next, we analyzed deletion landscapes from the serial passage in Vero cells. Although the pool of
400 viral deletion mutants for infection was initially all four sub-libraries, less than 1% of detectable
401 barcodes were from pMR766(-) libraries by the end of passage 2. The vast number of the observed
402 barcodes ($\approx 95\%$) were derived from the pMR766(+)_L library, with the remaining ($\approx 5\%$) from the
403 pMR766(+)_S library. One potential reason is that pMR766(-) genome replication was unable to be
404 rescued by the wild-type virus supplying NS5 in trans.

405

406 Of the initial 40,000 mappable barcodes of pMR766(+)_L, only 300 were detected after passage 1.
407 These were used to construct a deletion profile (Fig. 3F), which shows a single peak, centered at
408 *E*, that slopes downward in each direction to a deletion-depth of zero beyond the 5' border of *PrM*
409 and the 3' border of *NSI*. Importantly, Pr, M, and E are 3 of the 4 structural proteins that comprise
410 the viral particle (C is the last). By passage 2, several variants with 1-2 kb deletions that spanned
411 this region increased 200–500 \times in prevalence. Flavivirus replicon systems have previously been
412 developed by deletions in these regions, including C (41, 71). RanDeL-seq determined that ZIKV
413 tolerated deletions in prM and E, but not in C.

414

415 A final deletion landscape of ZIKV by Passage 2 (Fig. 3G) showed that only 3 kb genomic interval
416 of pMR766 can tolerate deletion. The region beginning exactly at Pr and ending precisely at the

417 end of NS1 is TAE1, and can be efficiently complemented in *trans*. The regions flanking TAE1
418 are cis-acting, with CAE1 encompassing the 5' UTR and CAE2 the remainder of the non-structural
419 genes and 3'UTR (NS2-3' UTR). Deletions within CAE1 or CAE2 were not detected upon
420 passage. We verified these results by two serial passages in C6/36 cells (Fig S8).

421

422 **Discussion**

423 We describe a high-throughput method (RanDeL-seq) to comprehensively map viral cis- and trans-
424 elements at a single-nucleotide resolution. RanDeL-seq takes advantage of *in vitro* transposition,
425 dual exonuclease chewback, and barcode cassettes to make randomly distributed deletions of
426 varying size throughout a sequence of interest. As a proof-of-concept, we built and screened
427 RanDeLs of >23,000 HIV-1 variants, and >90,000 ZIKV variants. Tracking and sequencing
428 barcodes at each stage of the scheme (transfection and passage to passage) revealed elements
429 critical for different stages in the viral life cycle, particularly transmission, and enabled mapping
430 of these elements in HIV-1 and ZIKV at single-base resolution.

431

432 The deletion landscape for HIV-1 recapitulated known CAEs (LTR, Ψ , RRE) and their roles in
433 transcription, encapsidation and egress. Despite previous claims that the Genomic RNA Packaging
434 Enhancer (GRPE) is important for encapsidation (40), deletions of this region (nucleotide position
435 2022-2188) did not affect mobilization, in agreement with the findings of Nikolaitchik and Hu
436 (72). The results also showed that the cPPT, despite its debated role in HIV-1 replication, was as
437 important for sustained viral replication as the LTR, Ψ , and RRE. Surprisingly, we also identified
438 a necessary 671-nucleotide region from the RRE to SA-7 which has not previously been reported
439 and the function of which is undetermined. Previous work suggested that deletion to upstream

440 cryptic splice sites 7a and 7b, but not SA-7, still allowed for HIV-1 replication (68). There were
441 no instances of mutants where SA7 remained intact, and SA7a and 7b were deleted, as evidenced
442 by the final HIV-1 deletion landscape. Additionally, SA-7 is heavily regulated, with an intronic
443 splicing silencer (ISS), exonic splicing silencer (ESS), and exonic splicing enhancer (ESE).
444 Interestingly, previous work suggested these elements were cis-acting (31, 73-75), but RanDeL-
445 seq shows only the ISS included in CAE3, and therefore deletion of the ESS and ESE was tolerated
446 or could be provided in *trans*.

447
448 Analysis of ZIKV deletion landscape, in two different cell types, showed that deletions in the C
449 protein, non-structural genes NS2–NS5, and UTRs are not tolerated and could not be supplemented
450 in *trans* by the wild-type virus. This ZIKV profile adds to established flavivirus CAE and TAE
451 models that focus on conserved elements of 5' and 3' UTRs (76); as seen with Yellow Fever (41),
452 West Nile Virus (77, 78), Dengue (79, 80), and Hepatitis C (81). While it accurately identifies the
453 highly structured UTRs as critical CAEs, RanDeL-seq also demonstrated that deletions in C, NS5,
454 and the other non-structural proteins (NS2-NS4) could not be complemented in *trans*. A recent
455 study of the same strain of ZIKV reached similar conclusions through transposon insertion instead
456 of deletion (82). Insertions in NS2-NS5 were not tolerated, except at the regions proximal to the
457 protein cleavage sites. However, that group found that insertions were tolerated in the C protein,
458 which RanDeL-seq labeled as a CAE.

459
460 We note a number of limitations to RanDeL-seq. First, the one-pot method can create extremely
461 diverse libraries *in vitro*, but transformation of *E. coli* limits the library diversity, due to selection
462 against potentially “toxic” or unstable sequences in viral genomes. This limitation is shown by the

463 finding that the initial deletion depths are not flat across the viral genome. Specific regions (i.e.
464 gag/pol HIV deletions) are still selected for despite having less coverage in the initial construction
465 and transfection. RanDeL-seq may also be too inefficient to produce diverse libraries for viruses
466 with much larger genomes, such as herpes viruses (encoded on 250 kb BACs) (83). Transformation
467 of bacteria with high molecular weight DNA is inefficient, and large genomes are easily damaged
468 by shearing during the physical manipulations required for cleanup. However, libraries could be
469 developed by dividing large genomes into smaller pieces that can be mutated separately and then
470 reassembled using suitable methods such as REXER (84) and could be incorporated into other
471 elegant frameworks for mapping DIPs (85).

472

473 The HIV-1 screen was conducted using a single molecular clone of HIV-1 and a single clonal cell
474 line (MT-4). It is possible that CAEs vary between viral strains and between cell lines and tissue
475 types. Conducting the screen in a tissue explants (PBMC or HLAC cultures) may reveal different
476 results. Also, the method is unable to monitor recombination between viruses (86), which could
477 produce viral strains that have acquired more than one deletion, and create linkage effects.
478 Similarly, no sequencing outside of the barcode cassette was done during serial passage,
479 precluding the detection of additional mutations. However, we show a strong correlation between
480 replicates, indicating that the observed selection was deterministic, rather than a result of drift.

481

482 Compared to pre-existing methods of CAE mapping, RanDeL-seq is able to cover the full viral
483 genome with random deletions of variable size, track barcode (i.e. specific mutations) prevalence
484 over time, and map at a single-nucleotide resolution. It is an improvement on methods of creating
485 viral deletion mutants that rely on site-directed mutagenesis, iterative deletion, or spontaneous DI

486 RNA emergence in culture; RanDeL-seq can comprehensively map full length viruses, not just
487 one targeted location. Additionally, RanDeL-seq fully abrogates genomic regions, rather than
488 silencing potential CAEs with SNPs, stop codons, or sequence changes that don't affect protein
489 synthesis. This full deletion allows determination of the essential nature of each genomic region.

490

491 The advantages of the method, along with its speed and low cost, make it attractive for studying
492 novel, emerging viruses. The method can be rapidly deployed to identify CAEs for antiviral drug
493 targeting, minimal sequences necessary for vaccine development, and candidates for novel
494 antiviral therapies such as TIPs. Collectively, RanDeL-seq could be a valuable and versatile
495 framework of general use to virology, aiding the study of viral replication mechanisms and the
496 development of novel antiviral therapeutics.

497

498

499

500

501 **References**

502

- 503 1. Jacob F, Monod J. 1961. Genetic regulatory mechanisms in the synthesis of proteins. *J Mol Biol*
504 3:318-56.
- 505 2. Nicholson BL, White KA. 2014. Functional long-range RNA-RNA interactions in positive-strand
506 RNA viruses. *Nat Rev Microbiol* 12:493-504.
- 507 3. Newburn LR, White KA. 2015. Cis-acting RNA elements in positive-strand RNA plant virus
508 genomes. *Virology* 479-480:434-43.
- 509 4. Romero-Lopez C, Berzal-Herranz A. 2013. Unmasking the information encoded as structural
510 motifs of viral RNA genomes: a potential antiviral target. *Rev Med Virol* 23:340-54.
- 511 5. Liu Y, Wimmer E, Paul AV. 2009. Cis-acting RNA elements in human and animal plus-strand
512 RNA viruses. *Biochim Biophys Acta* 1789:495-517.
- 513 6. Lim CS, Brown CM. 2017. Know Your Enemy: Successful Bioinformatic Approaches to Predict
514 Functional RNA Structures in Viral RNAs. *Front Microbiol* 8:2582.
- 515 7. Chen IH, Huang YW, Tsai CH. 2017. The Functional Roles of the Cis-acting Elements in Bamboo
516 mosaic virus RNA Genome. *Front Microbiol* 8:645.
- 517 8. Hermann T. 2016. Small molecules targeting viral RNA. *Wiley Interdiscip Rev RNA* 7:726-743.
- 518 9. Gasparian AV, Neznanov N, Jha S, Galkin O, Moran JJ, Gudkov AV, Gurova KV, Komar AA.
519 2010. Inhibition of encephalomyocarditis virus and poliovirus replication by quinacrine:
520 implications for the design and discovery of novel antiviral drugs. *J Virol* 84:9390-7.
- 521 10. Iwasaki M, Ngo N, Cubitt B, Teijaro JR, de la Torre JC. 2015. General Molecular Strategy for
522 Development of Arenavirus Live-Attenuated Vaccines. *J Virol* 89:12166-77.
- 523 11. Pena L, Sutton T, Chockalingam A, Kumar S, Angel M, Shao H, Chen H, Li W, Perez DR. 2013.
524 Influenza viruses with rearranged genomes as live-attenuated vaccines. *J Virol* 87:5118-27.
- 525 12. Jang YH, Seong BL. 2012. Principles underlying rational design of live attenuated influenza
526 vaccines. *Clin Exp Vaccine Res* 1:35-49.
- 527 13. Graham RL, Deming DJ, Deming ME, Yount BL, Baric RS. 2018. Evaluation of a recombination-
528 resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform. *Commun*
529 *Biol* 1:179.
- 530 14. Perez JT, Pham AM, Lorini MH, Chua MA, Steel J, tenOever BR. 2009. MicroRNA-mediated
531 species-specific attenuation of influenza A virus. *Nat Biotechnol* 27:572-6.
- 532 15. Tanner EJ, Kirkegaard KA, Weinberger LS. 2016. Exploiting Genetic Interference for Antiviral
533 Therapy. *PLoS Genet* 12:e1005986.

- 534 16. Huang AS, Baltimore D. 1970. Defective viral particles and viral disease processes. *Nature*
535 226:325-7.
- 536 17. Von Magnus P. 1954. Incomplete forms of influenza virus. *Advances in virus research* 2:59-79.
- 537 18. Knipe DM, Howley PM. 2013. *Fields Virology*. Lippincott Williams & Wilki 6th ed:2644.
- 538 19. Henle W, Henle G. 1943. Interference of Inactive Virus with the Propagation of Virus of Influenza.
539 *Science* 98:87-9.
- 540 20. Frensing T, Pflugmacher A, Bachmann M, Peschel B, Reichl U. 2014. Impact of defective
541 interfering particles on virus replication and antiviral host response in cell culture-based influenza
542 vaccine production. *Appl Microbiol Biotechnol* 98:8999-9008.
- 543 21. Poirier EZ, Mounce BC, Rozen-Gagnon K, Hooikaas PJ, Stapleford KA, Moratorio G, Vignuzzi
544 M. 2015. Low-Fidelity Polymerases of Alphaviruses Recombine at Higher Rates To Overproduce
545 Defective Interfering Particles. *J Virol* 90:2446-54.
- 546 22. Rezelj VV, Levi LI, Vignuzzi M. 2018. The defective component of viral populations. *Curr Opin*
547 *Virol* 33:74-80.
- 548 23. Kupke SY, Riedel D, Frensing T, Zmora P, Reichl U. 2019. A Novel Type of Influenza A Virus-
549 Derived Defective Interfering Particle with Nucleotide Substitutions in Its Genome. *J Virol* 93.
- 550 24. Dimmock NJ, Easton AJ. 2014. Defective interfering influenza virus RNAs: time to reevaluate
551 their clinical potential as broad-spectrum antivirals? *J Virol* 88:5217-27.
- 552 25. Dimmock NJ, Rainsford EW, Scott PD, Marriott AC. 2008. Influenza virus protecting RNA: an
553 effective prophylactic and therapeutic antiviral. *J Virol* 82:8570-8.
- 554 26. Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. 2019. Advances in
555 respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.
556 *Antiviral Res* 167:45-67.
- 557 27. Wolter F, Puchta H. 2018. Application of CRISPR/Cas to Understand Cis- and Trans-Regulatory
558 Elements in Plants. *Methods Mol Biol* 1830:23-40.
- 559 28. Morelli A, Cabezas Y, Mills LJ, Seelig B. 2017. Extensive libraries of gene truncation variants
560 generated by in vitro transposition. *Nucleic Acids Res* 45:e78.
- 561 29. Pockock GM, Zimdars LL, Yuan M, Eliceiri KW, Ahlquist P, Sherer NM. 2017. Diverse activities
562 of viral cis-acting RNA regulatory elements revealed using multicolor, long-term, single-cell
563 imaging. *Mol Biol Cell* 28:476-487.
- 564 30. Diao Y, Fang R, Li B, Meng Z, Yu J, Qiu Y, Lin KC, Huang H, Liu T, Marina RJ, Jung I, Shen Y,
565 Guan KL, Ren B. 2017. A tiling-deletion-based genetic screen for cis-regulatory element
566 identification in mammalian cells. *Nat Methods* 14:629-635.
- 567 31. Takata MA, Soll SJ, Emery A, Blanco-Melo D, Swanstrom R, Bieniasz PD. 2018. Global
568 synonymous mutagenesis identifies cis-acting RNA elements that regulate HIV-1 splicing and
569 replication. *PLoS Pathog* 14:e1006824.

- 570 32. Smyth RP, Despons L, Huili G, Bernacchi S, Hijnen M, Mak J, Jossinet F, Weixi L, Paillart JC,
571 von Kleist M, Marquet R. 2015. Mutational interference mapping experiment (MIME) for studying
572 RNA structure and function. *Nat Methods* 12:866-72.
- 573 33. Smyth RP, Smith MR, Jousset AC, Despons L, Laumond G, Decoville T, Cattenoz P, Moog C,
574 Jossinet F, Mougél M, Paillart JC, von Kleist M, Marquet R. 2018. In cell mutational interference
575 mapping experiment (in cell MIME) identifies the 5' polyadenylation signal as a dual regulator of
576 HIV-1 genomic RNA production and packaging. *Nucleic Acids Res* 46:e57.
- 577 34. Firth AE. 2014. Mapping overlapping functional elements embedded within the protein-coding
578 regions of RNA viruses. *Nucleic Acids Res* 42:12425-39.
- 579 35. Chen MH, Frey TK. 1999. Mutagenic analysis of the 3' cis-acting elements of the rubella virus
580 genome. *J Virol* 73:3386-403.
- 581 36. Goodfellow I, Chaudhry Y, Richardson A, Meredith J, Almond JW, Barclay W, Evans DJ. 2000.
582 Identification of a cis-acting replication element within the poliovirus coding region. *J Virol*
583 74:4590-600.
- 584 37. Guo J, Han J, Lin J, Finer J, Dorrance A, Qu F. 2017. Functionally interchangeable cis-acting RNA
585 elements in both genome segments of a picorna-like plant virus. *Sci Rep* 7:1017.
- 586 38. Liu ZY, Yu JY, Huang XY, Fan H, Li XF, Deng YQ, Ji X, Cheng ML, Ye Q, Zhao H, Han JF, An
587 XP, Jiang T, Zhang B, Tong YG, Qin CF. 2017. Characterization of cis-Acting RNA Elements of
588 Zika Virus by Using a Self-Splicing Ribozyme-Dependent Infectious Clone. *J Virol* 91.
- 589 39. Moomau C, Musalgaonkar S, Khan YA, Jones JE, Dinman JD. 2016. Structural and Functional
590 Characterization of Programmed Ribosomal Frameshift Signals in West Nile Virus Strains Reveals
591 High Structural Plasticity Among cis-Acting RNA Elements. *J Biol Chem* 291:15788-95.
- 592 40. Chamanian M, Purzycka KJ, Wille PT, Ha JS, McDonald D, Gao Y, Le Grice SF, Arts EJ. 2013.
593 A cis-acting element in retroviral genomic RNA links Gag-Pol ribosomal frameshifting to selective
594 viral RNA encapsidation. *Cell Host Microbe* 13:181-92.
- 595 41. Corver J, Lenches E, Smith K, Robison RA, Sando T, Strauss EG, Strauss JH. 2003. Fine mapping
596 of a cis-acting sequence element in yellow fever virus RNA that is required for RNA replication
597 and cyclization. *J Virol* 77:2265-70.
- 598 42. Lin YJ, Liao CL, Lai MM. 1994. Identification of the cis-acting signal for minus-strand RNA
599 synthesis of a murine coronavirus: implications for the role of minus-strand RNA in RNA
600 replication and transcription. *J Virol* 68:8131-40.
- 601 43. Trobridge G, Josephson N, Vassilopoulos G, Mac J, Russell DW. 2002. Improved foamy virus
602 vectors with minimal viral sequences. *Mol Ther* 6:321-8.
- 603 44. van Ooij MJ, Polacek C, Glaudemans DH, Kuijpers J, van Kuppeveld FJ, Andino R, Agol VI,
604 Melchers WJ. 2006. Polyadenylation of genomic RNA and initiation of antigenomic RNA in a
605 positive-strand RNA virus are controlled by the same cis-element. *Nucleic Acids Res* 34:2953-65.
- 606 45. Kirkegaard K, Nelsen B. 1990. Conditional poliovirus mutants made by random deletion
607 mutagenesis of infectious cDNA. *J Virol* 64:185-94.


- 608 46. Krishnakumar R, Grose C, Haft DH, Zaveri J, Alperovich N, Gibson DG, Merryman C, Glass JI.
609 2014. Simultaneous non-contiguous deletions using large synthetic DNA and site-specific
610 recombinases. *Nucleic Acids Res* 42:e111.
- 611 47. Fulton BO, Sachs D, Beaty SM, Won ST, Lee B, Palese P, Heaton NS. 2015. Mutational Analysis
612 of Measles Virus Suggests Constraints on Antigenic Variation of the Glycoproteins. *Cell Rep*
613 11:1331-8.
- 614 48. Heaton NS, Sachs D, Chen CJ, Hai R, Palese P. 2013. Genome-wide mutagenesis of influenza virus
615 reveals unique plasticity of the hemagglutinin and NS1 proteins. *Proc Natl Acad Sci U S A*
616 110:20248-53.
- 617 49. Iverson EA, Goodman DA, Gorchels ME, Stedman KM. 2017. Extreme Mutation Tolerance:
618 Nearly Half of the Archaeal Fusellovirus *Sulfolobus* Spindle-Shaped Virus 1 Genes Are Not
619 Required for Virus Function, Including the Minor Capsid Protein Gene vp3. *J Virol* 91.
- 620 50. Wang L, Liu SY, Chen HW, Xu J, Chapon M, Zhang T, Zhou F, Wang YE, Quanquin N, Wang G,
621 Tian X, He Z, Liu L, Yu W, Sanchez DJ, Liang Y, Jiang T, Modlin R, Bloom BR, Li Q, Deng JC,
622 Zhou P, Qin FX, Cheng G. 2017. Generation of a Live Attenuated Influenza Vaccine that Elicits
623 Broad Protection in Mice and Ferrets. *Cell Host Microbe* 21:334-343.
- 624 51. Levy SF, Blundell JR, Venkataram S, Petrov DA, Fisher DS, Sherlock G. 2015. Quantitative
625 evolutionary dynamics using high-resolution lineage tracking. *Nature* 519:181-6.
- 626 52. Bhasin A, Goryshin IY, Steiniger-White M, York D, Reznikoff WS. 2000. Characterization of a
627 Tn5 pre-cleavage synaptic complex. *J Mol Biol* 302:49-63.
- 628 53. Goryshin IY, Reznikoff WS. 1998. Tn5 in vitro transposition. *J Biol Chem* 273:7367-74.
- 629 54. Reznikoff WS, Goryshin IY, Jendrisak JJ. 2004. Tn5 as a molecular genetics tool: In vitro
630 transposition and the coupling of in vitro technologies with in vivo transposition. *Methods Mol*
631 *Biol* 260:83-96.
- 632 55. Jayaraman B, Crosby DC, Homer C, Ribeiro I, Mavor D, Frankel AD. 2014. RNA-directed
633 remodeling of the HIV-1 protein Rev orchestrates assembly of the Rev-Rev response element
634 complex. *Elife* 3:e04120.
- 635 56. Hansen MMK, Wen WY, Ingerman E, Razoooky BS, Thompson CE, Dar RD, Chin CW, Simpson
636 ML, Weinberger LS. 2018. A Post-Transcriptional Feedback Mechanism for Noise Suppression
637 and Fate Stabilization. *Cell* 173:1609-1621 e15.
- 638 57. Van Maele B, De Rijck J, De Clercq E, Debysers Z. 2003. Impact of the central polypurine tract on
639 the kinetics of human immunodeficiency virus type 1 vector transduction. *J Virol* 77:4685-94.
- 640 58. Riviere L, Darlix JL, Cimarelli A. 2010. Analysis of the viral elements required in the nuclear
641 import of HIV-1 DNA. *J Virol* 84:729-39.
- 642 59. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P. 2000. HIV-1 genome
643 nuclear import is mediated by a central DNA flap. *Cell* 101:173-85.

- 644 60. Charneau P, Clavel F. 1991. A single-stranded gap in human immunodeficiency virus unintegrated
645 linear DNA defined by a central copy of the polypurine tract. *J Virol* 65:2415-21.
- 646 61. Arhel N, Munier S, Souque P, Mollier K, Charneau P. 2006. Nuclear import defect of human
647 immunodeficiency virus type 1 DNA flap mutants is not dependent on the viral strain or target cell
648 type. *J Virol* 80:10262-9.
- 649 62. Hu C, Saenz DT, Fadel HJ, Walker W, Peretz M, Poeschla EM. 2010. The HIV-1 central polypurine
650 tract functions as a second line of defense against APOBEC3G/F. *J Virol* 84:11981-93.
- 651 63. Yamashita M, Emerman M. 2005. The cell cycle independence of HIV infections is not determined
652 by known karyophilic viral elements. *PLoS Pathog* 1:e18.
- 653 64. Dvorin JD, Bell P, Maul GG, Yamashita M, Emerman M, Malim MH. 2002. Reassessment of the
654 roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear
655 import. *J Virol* 76:12087-96.
- 656 65. Marsden MD, Zack JA. 2007. Human immunodeficiency virus bearing a disrupted central DNA
657 flap is pathogenic in vivo. *J Virol* 81:6146-50.
- 658 66. Ocwieja KE, Sherrill-Mix S, Mukherjee R, Custers-Allen R, David P, Brown M, Wang S, Link
659 DR, Olson J, Travers K, Schadt E, Bushman FD. 2012. Dynamic regulation of HIV-1 mRNA
660 populations analyzed by single-molecule enrichment and long-read sequencing. *Nucleic Acids Res*
661 40:10345-55.
- 662 67. Sertznig H, Hillebrand F, Erkelenz S, Schaal H, Widera M. 2018. Behind the scenes of HIV-1
663 replication: Alternative splicing as the dependency factor on the quiet. *Virology* 516:176-188.
- 664 68. Purcell DF, Martin MA. 1993. Alternative splicing of human immunodeficiency virus type 1
665 mRNA modulates viral protein expression, replication, and infectivity. *J Virol* 67:6365-78.
- 666 69. Schwarz MC, Sourisseau M, Espino MM, Gray ES, Chambers MT, Tortorella D, Evans MJ. 2016.
667 Rescue of the 1947 Zika Virus Prototype Strain with a Cytomegalovirus Promoter-Driven cDNA
668 Clone. *mSphere* 1.
- 669 70. Li D, Aaskov J, Lott WB. 2011. Identification of a cryptic prokaryotic promoter within the cDNA
670 encoding the 5' end of dengue virus RNA genome. *PLoS One* 6:e18197.
- 671 71. Jones CT, Patkar CG, Kuhn RJ. 2005. Construction and applications of yellow fever virus
672 replicons. *Virology* 331:247-59.
- 673 72. Nikolaitchik OA, Hu WS. 2014. Deciphering the role of the Gag-Pol ribosomal frameshift signal
674 in HIV-1 RNA genome packaging. *J Virol* 88:4040-6.
- 675 73. Stoltzfus CM, Madsen JM. 2006. Role of viral splicing elements and cellular RNA binding proteins
676 in regulation of HIV-1 alternative RNA splicing. *Curr HIV Res* 4:43-55.
- 677 74. Grewe B, Ehrhardt K, Hoffmann B, Blissenbach M, Brandt S, Uberla K. 2012. The HIV-1 Rev
678 protein enhances encapsidation of unspliced and spliced, RRE-containing lentiviral vector RNA.
679 *PLoS One* 7:e48688.

- 680 75. Tange TO, Damgaard CK, Guth S, Valcarcel J, Kjems J. 2001. The hnRNP A1 protein regulates
681 HIV-1 tat splicing via a novel intron silencer element. *EMBO J* 20:5748-58.
- 682 76. Liu ZY, Li XF, Jiang T, Deng YQ, Zhao H, Wang HJ, Ye Q, Zhu SY, Qiu Y, Zhou X, Qin ED,
683 Qin CF. 2013. Novel cis-acting element within the capsid-coding region enhances flavivirus viral-
684 RNA replication by regulating genome cyclization. *J Virol* 87:6804-18.
- 685 77. Zhang B, Dong H, Zhou Y, Shi PY. 2008. Genetic interactions among the West Nile virus
686 methyltransferase, the RNA-dependent RNA polymerase, and the 5' stem-loop of genomic RNA. *J*
687 *Virol* 82:7047-58.
- 688 78. Lo MK, Tilgner M, Bernard KA, Shi PY. 2003. Functional analysis of mosquito-borne flavivirus
689 conserved sequence elements within 3' untranslated region of West Nile virus by use of a reporting
690 replicon that differentiates between viral translation and RNA replication. *J Virol* 77:10004-14.
- 691 79. Men R, Bray M, Clark D, Chanock RM, Lai CJ. 1996. Dengue type 4 virus mutants containing
692 deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell
693 culture and altered viremia pattern and immunogenicity in rhesus monkeys. *J Virol* 70:3930-7.
- 694 80. Manzano M, Reichert ED, Polo S, Falgout B, Kasprzak W, Shapiro BA, Padmanabhan R. 2011.
695 Identification of cis-acting elements in the 3'-untranslated region of the dengue virus type 2 RNA
696 that modulate translation and replication. *J Biol Chem* 286:22521-34.
- 697 81. Arumugaswami V, Remenyi R, Kanagavel V, Sue EY, Ngoc Ho T, Liu C, Fontanes V, Dasgupta
698 A, Sun R. 2008. High-resolution functional profiling of hepatitis C virus genome. *PLoS Pathog*
699 4:e1000182.
- 700 82. Fulton BO, Sachs D, Schwarz MC, Palese P, Evans MJ. 2017. Transposon Mutagenesis of the Zika
701 Virus Genome Highlights Regions Essential for RNA Replication and Restricted for Immune
702 Evasion. *J Virol* 91.
- 703 83. Berto E, Bozac A, Marconi P. 2005. Development and application of replication-incompetent HSV-
704 1-based vectors. *Gene Ther* 12 Suppl 1:S98-102.
- 705 84. Wang K, Fredens J, Brunner SF, Kim SH, Chia T, Chin JW. 2016. Defining synonymous codon
706 compression schemes by genome recoding. *Nature* 539:59-64.
- 707 85. Alnaji FG, Holmes JR, Rendon G, Vera JC, Fields CJ, Martin BE, Brooke CB. 2019. Sequencing
708 Framework for the Sensitive Detection and Precise Mapping of Defective Interfering Particle-
709 Associated Deletions across Influenza A and B Viruses. *J Virol* 93.
- 710 86. Levy DN, Aldrovandi GM, Kutsch O, Shaw GM. 2004. Dynamics of HIV-1 recombination in its
711 natural target cells. *Proc Natl Acad Sci U S A* 101:4204-9.
- 712 87. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production
713 of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells
714 transfected with an infectious molecular clone. *J Virol* 59:284-91.
- 715 88. Yanisch-Perron C, Vieira J, Messing J. 1985. Improved M13 phage cloning vectors and host
716 strains: nucleotide sequences of the M13mp18 and pUC19 vectors. *Gene* 33:103-19.

- 717 89. Vermeire J, Naessens E, Vanderstraeten H, Landi A, Iannucci V, Van Nuffel A, Taghon T, Pizzato
718 M, Verhasselt B. 2012. Quantification of reverse transcriptase activity by real-time PCR as a fast
719 and accurate method for titration of HIV, lenti- and retroviral vectors. *PLoS One* 7:e50859.
- 720 90. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time
721 quantitative PCR and the $2^{-\Delta\Delta C(T)}$ Method. *Methods* 25:402-8.
- 722 91. Baer A, Kehn-Hall K. 2014. Viral concentration determination through plaque assays: using
723 traditional and novel overlay systems. *J Vis Exp* doi:10.3791/52065:e52065.
- 724 92. Mandell DJ, Lajoie MJ, Mee MT, Takeuchi R, Kuznetsov G, Norville JE, Gregg CJ, Stoddard BL,
725 Church GM. 2015. Biocontainment of genetically modified organisms by synthetic protein design.
726 *Nature* 518:55-60.
727
- 728
- 729
- 730
- 731
- 732
- 733

734 Notton et al. Figure 1



735 **Figure 1: Method to generate a Random Deletion Library in HIV-1**

736 A. Overview schematic of method to create a barcoded random deletion library: (1) Transposon
737 cassettes harboring unique restriction sites are inserted into plasmids via in vitro transposition. (2)
738 Transposons are excised to linearize the insertion library with a meganuclease. (3) Deletions are
739 performed by chewback from both DNA termini by simultaneous treatment with enzyme blend.
740 Mean deletion size is modulated by adjusting duration of chewback. (4) The chewed termini are
741 end-repaired, dA-tailed, then joined by ligation to a T-tailed 60bp unique barcode cassette.

742 B. Schematic of the “TN5MK” synthetic meganuclease transposon cassette used in library
743 construction: TN5MK is composed of an antibiotic resistance gene, neomycin phosphotransferase
744 I (npt), flanked by meganuclease restriction sites for I-SceI and I-CeuI and Tn5 mosaic ends (gray
745 triangles) at the termini. The transposon cassette also contains a unique internal BamHI recognition
746 site.

747 C. The HIV-1 molecular clone pNL4-3, is a 14825 bp plasmid harboring the 9709 bp NL4-3
748 provirus (HIV-1 subtype B). NL4-3 is a chimera of two viruses (NY5 and LAV).

749 D. Library insertion, excision, barcoding details: Circular DNA (1) is linearized by digestion with
750 a meganuclease (I-SceI or I-CeuI), which cleaves at recognition sites encoded on the inserted
751 transposon. This creates linear DNA with 4 base 3’ overhangs (2). Deletions are created by
752 bidirectional chewback. Treatment with two exonucleases (T4 and RecJf) creates a population of
753 truncated deletion mutants with ragged ends (3). Ragged DNA ends are blunted and then prepared
754 for barcode cassette ligation by 5’ dephosphorylation and addition of a single 3’-dA (4). Deletion
755 mutants are re-ligated in presence of a barcode cassette with single 3’-dT overhangs and 5’
756 phosphoryl groups to create barcoded circular DNAs with 2 nicks separated by 60 bp (5).

757 E. Insertion libraries following I-SceI (S) or I-CeuI (C) digestion. Digestion of pNL43 insertion
758 library shows excisions of the TN5MK transposon (1.4kb) and upward shift of the supercoiled
759 library vs. the undigested library. Lanes: (M) 2 log DNA ladder, (1) undigested insertion library,
760 (2) I-SceI digested insertion library, (3) I-CeuI digested insertion library.

761 F. Location of TN5MK insertions for a subset of 7559 transposon integrations (3844 were unique).

762 G. Determination of enzymatic chewback rate for deletion size: The chewback rate was determined
763 by treating a 4 kb fragment of linear dsDNA with RecJf and T4 exonucleases in the presence of

764 SSB and no dNTPs for increasing amounts of time, then halting enzymatic activity. Reactions
765 were performed in triplicate. DNA concentrations were established by quantifying fluorescence of
766 PicoGreen in a plate reader in comparison to a dsDNA standard of known concentration.


767 H. Validation of Deletion Library: The pNL4-3 insertion library and pNL4-3 deletion library were
768 either not digested (\emptyset) or cut with I-CeuI (C) and then subjected to binary treatment with RecBCD,
769 which digests linear DNA to completion. Lanes 1-4 are the pNL43 insertion library and Lanes 5-
770 8 are the pNL43 deletion library.

771 I. pNL4-31 is composed of 23,851 tagged mutants with a range of deletion sizes. The right-skewed
772 (i.e. right-tailed) histogram of deletion sizes in pNL4-31, with bins of 100 bp (shown in blue) is
773 well-fit by a Gamma distribution (green, broken-line). Inset: Number of deletions detected within
774 each region of the HIV genome.

775 J. Deletion Depth Profile over the full HIV-1 genome. Calculation of the deletion depth profile of
776 the pNL4-31 genome indicates that each base is covered by hundreds to thousands of deletion
777 mutants. Two regions where deletions are not tolerated in the plasmid backbone are ori, the origin
778 of replication and bla, -lactamase, the resistance marker

779

780 Notton et al. Figure 2



781 **Figure 2: Genetic Screen of random deletion library to map viral cis- and trans- elements**

782 A. Block design of high-MOI passage. Wild-type NL4-3 and deletion library plasmids co-
783 transfected 293T cells. Virus-containing supernatant infected MT-4 cells in triplicate (K, L, M) at
784 high MOI. Infections were passaged at the end of every week, for 4 weeks. At the same time, flasks
785 with only NL4-3 wild-type virus were passaged identically (A, B, C not shown).

786 B. Passage details of high MOI screen. MT-4 cells (blue double discs) are infected at high MOI
787 with a pool of virus (HIV-1) containing both wild-type (red stars) and deletion mutants (blue stars).
788 At days 1 and 2, additional naïve MT-4 were added and the culture volume expanded. On day 3,
789 cell-free supernatant was harvested, and virus purified by ultracentrifugation for transfer or
790 analysis. One passage corresponds to 3 rounds of replication.

791 C. Detection and quantification of barcode cassettes by RT-qPCR. Genomic percentage of
792 barcoded mutants to total HIV genomes in transfection (293T), each stage of high MOI passage
793 (P3-P12), and a wild-type HIV control (WT). RT-qPCR data was normalized to a MS2 RNA spike-
794 in. Error bars are standard deviation from averaging each flask (K, L, M) per passage.

795 D. Representative deletion variant trajectories during high MOI passage. The slope in prevalence
796 versus passage number was determined by linear regression and classified deletions as adaptive,
797 neutral or deleterious. Data points correspond to the triplicate flasks (K, L, M) at each passage.
798 Prevalence is in reference to the total barcode cassette pool (tagged mutants).

799 E. Distribution of fitness in deletion variants that are not extinct by passage 12. The dashed vertical
800 line marks the neutral fitness boundary (slope of 0). 1390 of 4390 persistent mutants were adaptive.

801 F. The deletion depth profile of poly(A) RNA from transfected 293T cells, representing mutants
802 able to be transcribed.

803 G. The deletion depth profile built from the virus-containing supernatant of transfected 293T
804 representing mutants able to be transcribed, encapsulated, and egressed.

805 H. Deletion depth profile from virus-containing supernatant after 3 passages.


806 I. Deletion depth profile after 6 passages.

807 J. A model of HIV-1 cis- and trans-acting elements after 12 passages. The HIV-1 genome is
808 composed of 4 cis-acting elements, CAE1–CAE4, (highlighted in blue) and 3 trans-acting
809 elements, TAE1–TAE3, (highlighted in green).

810

811 Notton et al. Figure 3

812



813

814

815 **Figure 3: Application of RanDeL-seq to map Zika Virus (ZIKV) cis elements.**

816 A. pMR766(+), a Zika virus molecular clone. The MR766 Zika virus genome is encoded as a
817 cDNA driven by the CMV IE2 promoter. At the 3' end of the genome, a self-cleaving Hepatitis
818 Delta ribozyme allows for creation of an authentic 3' end post-transcription. An intron sequence
819 is present within NS1 to allow maintenance in bacteria but is spliced out during transcription in
820 host cells.

821 B. Restriction enzyme characterization of completed ZIKV deletion libraries compared to insertion
822 libraries ("ins."). (+) and (-) designate the template ZIKV plasmid. "S" and "L" designate the
823 chewback length for deletion libraries. Undigested, completed deletion libraries (Lanes 1-4) were
824 run next to undigested insertion libraries (Lanes 5-6). Insertion libraries (Lanes 7-10) treated with
825 I-SceI or I-CeuI to excise transposon (~1.4 kb). Deletion libraries linearized by unique ZIKV cutter
826 KpnI (Lanes 11-14).

827 C. Deletion depth profile of the pMR766(+)_L library. The ZIKV genome is well-represented in
828 the pMR766(+)_L library, with some bias. Each base of the ZIKV genome is covered by several
829 hundred different deletion mutants.

830 D. Detection and quantification of ZIKV barcode cassettes by RT-qPCR. Genomic percentage of
831 barcoded mutants to total ZIKV genomes at each day in passage 1 of the high MOI screen, and a
832 wild-type ZIKV control (WT). RT-qPCR data was normalized to a MS2 RNA spike-in.

833 E. Deletion Depth Profile of intracellular RNA of 293T co-transfected with the wild-type ZIKV
834 plasmid and the pooled deletion libraries.

835 F. Deletion Depth Profile of pMR766(+)_L after Passage 1. Only deletions in Pr-NS1 can be trans-
836 complemented by wild-type ZIKV.

837 G. Final map of ZIKV cis- and trans-acting elements after Passage 2. The two cis-acting regions
838 are highlighted in blue and do not tolerate deletion (i.e., must be present for efficient transmission
839 to occur). The trans-acting region is highlighted in green and can be complemented in trans (i.e.,
840 if deleted, transmission occurs by complementation from wild-type virus).

841

842

843 **Materials and Methods**

844

845 **Plasmids:** pNL4-3 is a molecular clone of HIV-1 subtype B (87), and was a kind gift of Malcom
846 Martin (AIDS Reagent Program #114). Two molecular clones of ZIKV, strain MR-766, were a
847 generous gift from Matthew Evans. Two versions were available: a wild-type clone, pMR766(+),
848 and a mutant, pMR766(-). The mutant clone has a GDD→GNN mutation in NS5 and lacks a
849 functional RNA Dependent RNA Polymerase.

850

851 **Cells:** All cells were grown at 37°C with 5% CO₂. HEK 293T cells and C6/36 *Aedes*
852 *albopictus* cells (American Type Culture Collection, # CRL-3216 and CRL-1660, respectively)
853 were propagated in DMEM supplemented with 10% FBS (Fisher Scientific) and 1% Pen/Strep
854 (Fisher Scientific), referred to as D10. Vero cells (African green monkey [*Cercopithecus aethiops*]
855 kidney cells) (ATCC, # CCL-81) were also propagated in D10. MT-4 cells (NIH AIDS Reagent
856 Program, #120) were propagated in RPMI 1640 supplemented with 10% FBS, 1% Pen/Strep,
857 HEPES, and L-glutamine, referred to as R10.

858

859 **Reagent sourcing:** All enzymes were obtained from New England Biolabs (NEB; Billerica, MA,
860 USA) unless indicated otherwise. All chemicals were obtained from Sigma-Aldrich (St. Louis,
861 MO, USA), unless indicated otherwise. DNA oligonucleotides and synthetic dsDNA were
862 obtained from Integrated DNA Technologies (Coralville, IA, USA).

863

864 **Transposon DNA cassettes:** Transposon cassettes were ordered in 3 pieces as synthetic dsDNA
865 (<500 bp) (gBlocks, IDT) and cloned by Gibson Assembly into pUC19 (linearized at the BamHI

866 site) (88). Post assembly, linear transposon cassettes were constructed by standard Q5 Hotstart
867 PCR protocol (NEB) with TN5MK plasmid template and the oligos, oTN5-F and oTN5-R (IDT).
868 The template was amplified under the following conditions: 98°C for 30 seconds; 15 cycles of:
869 98°C for 10 seconds, 68°C for 20 seconds, 72°C for 50 seconds; final extension: 72°C for 5 min,
870 hold at 10° C. PCR products were purified by column with Zymo DCC-5 Kit (Zymo Research),
871 then analyzed on a 0.8% agarose/TE gel. The 1.4 kb transposon cassettes were excised and cleaned
872 using Qiagen Gel Extraction Kit (Qiagen) and Zymo DNA columns.

873

874 **Barcode DNA cassettes:** HIV-1 barcodes were blunt-end, 5'-phosphorylated, 60 bp DNA
875 cassettes prepared by standard Q5 Hotstart PCR with BC20v1-F and BC20v1-R on the
876 oligonucleotide pool BC20-T (IDT). Oligos sequences can be found in Table S2. BC20-T oligos
877 were 60 bp ssDNA molecules with consensus 20 bp flanking sequences and a middle 20 bp with
878 machine-mixed bases (random sequences for barcodes). Reactions were cycled at 98°C for 30
879 seconds; 5 cycles of: 98°C for 10 seconds, 65°C for 75 seconds; 1 cycle of: 65°C for 5 min, hold
880 at 10° C. Post-PCR, barcode cassettes were column purified (Zymo). A 3'-dT overhang was added
881 with a 3'→5' exonuclease-deficient Klenow Fragment of *E. coli* DNA Polymerase I per
882 manufacturer's protocol. The reaction was incubated at 37°C for 3 hours. Post-incubation, DNA
883 was cleaned by column-purification (Zymo) and eluted in Tris-acetate-EDTA buffer.

884 ZIKV libraries were prepared identically with a slight difference in the forward and reverse
885 common sequences of the barcode cassette (BC20v2-F, BC20v2-R). These sequences modified a
886 triple repeat in the forward barcode read (GGG) to avoid problems with sequencing of low-
887 diversity libraries on the Illumina HiSeq4000.

888

889 **Chewback Conditions:** Template DNA, λ -HindIII, was initially heated to 60°C for 3 minutes and
890 immediately cooled to separate annealed cohesive cos ends. A standard 50 ul chewback reaction
891 was prepared on ice by combining dH₂O, 10X NEB2.1, λ -HindIII DNA template (500 ng/ul), T4
892 DNA Polymerase (3 U/ul), RecJ_f (30 U/ul), and ET SSB (500 ng/ul). The reaction was then
893 incubated at 37° C. After 30 minutes, 1 ul of 10 mM dNTPs were added, the reaction mixed, and
894 returned to 37°C for 11 minutes to allow T4 DNA Polymerase to fill in recessed ends. The reaction
895 was halted by adding EDTA (pH 8.0) to a final concentration of 20 mM. Various dropout reactions
896 were conducted, where dH₂O was substituted for enzymes.

897

898 **Determination of Chewback Rate:** A 4.3 kb dsDNA template was obtained by purifying the
899 4361 bp fragment of λ -HindIII digest. The λ -HindIII template was run out on a 0.8% agarose gel,
900 stained with SYBR Safe, and excised. DNA was recovered by adding 0.1 gel volumes of β -agarase
901 I reaction buffer (NEB), melting gel slices briefly at 65°C, cooling to 42°C, and immediately
902 adding 1 U of β -agarase I per 100 ul of molten gel (NEB). The mixture was incubated at 42°C for
903 60 min to release DNA bound in the agarose matrix. DNA was precipitated from the digested
904 fraction with sodium acetate (3M) and 2-propanol. After mixing, the reaction was spun at 20000×g
905 for 15 min at 25°C, and the supernatant aspirated. The DNA pellet was washed once with 70%
906 ethanol, allowed to air dry briefly, then dissolved in TE.

907 A chewback reaction was set up per minimal conditions and incubated at 37°C. At 0, 5, 10, 15, 20,
908 25, 30, 40, 50, 60, 70, and 80 minutes of incubation, an aliquot of the reaction was removed and
909 combined with equal volume dNTP buffer (NEB2.1, 10mM dNTP, dH₂O). These 12 reactions
910 were then incubated at 37°C for 11 min to allow T4 DNA Polymerase to fill in the single-stranded

911 tails that remain uncleaved by RecJ_f. After 11 min of fill-in, the reaction was halted with an equal
912 volume of Stop Buffer (EDTA, dH₂O).

913 The concentration of dsDNA was determined by a fluorimetric method (PicoGreen, Thermo Fisher
914 Scientific). Each reaction was diluted in TE and mixed with a PicoGreen working stock (diluted
915 to 1/200× in TE Buffer) to be read with an Enspire plate reader (Perkin Elmer) with 480 nm
916 excitation and 520 nm emission filter. Fluorescence was compared to a λ DNA standard. All
917 reactions were performed in triplicate. Chewback rates at 37°C were calculated by fitting the decay
918 in dsDNA (fluorescence signal) at various timepoints to a linear regression model with the freely
919 available R statistical software.

920

921 **Construction of RanDeL**

922 *DNA extraction, precipitation, and wash:* Throughout construction of the random deletion
923 libraries, DNA was extracted, precipitated and washed with the same methods. DNA samples were
924 extracted with 25:24:1 phenol:chloroform:isoamyl alcohol equilibrated with TE, followed by a
925 second extraction with pure chloroform (Sigma-Aldrich). The upper aqueous layer was transferred
926 to a new DNA LoBind tube, and 25 ug of co-precipitating GenElute Linear Polyacrylamide
927 (Sigma-Aldrich) added and the solution mixed to homogeneity. DNA samples were precipitated
928 from the aqueous phase by MgCl₂/PEG-8000 precipitation. Samples were adjusted to a final
929 concentration of 12.5% (m/v) PEG-8000 and 20 mM MgCl₂ by adding MgCl₂ (1M) and 50%
930 (m/v) PEG-8000. Reactions were inverted and flicked to mix, then spun at 20000×g for 60 minutes
931 in a refrigerated microcentrifuge (Eppendorf) at 25°C to pellet all precipitated DNA. After
932 centrifugation, supernatants were removed and discarded. Freshly prepared 70% ethanol was
933 added and the reactions mixed by inversion. Samples were spun at 20000×g for 2 minutes to collect

934 the pellet, then aspirate and discard the supernatant. Additional ethanol was added to wash the
935 pellet, and samples were spun again at 20000×g for 2 minutes to collect DNA pellets. All
936 supernatants were carefully removed and the pellet dried briefly at room temperature (5 minutes)
937 until no visible liquid remained. DNA samples were solubilized by adding TE, incubating the tube
938 at 42°C for 20 minutes and mixed by flicking the tube.

939

940 *In Vitro Transposition:* Transposon Cassettes were inserted into pNL4-3 by *in vitro* transposition
941 with EZ-Tn5 transposase (Epicentre) per manufacturer's protocol and with equal mols of plasmid
942 template and transposon. After a two-hour incubation in reaction buffer at 37°C, the reaction was
943 halted with 1% SDS solution and heated to 70°C for 10 minutes. The entire volume of the reaction
944 was transferred onto a 0.025 um membrane floating on TE. Drop dialysis was allowed to proceed
945 for 1 hour. Plasmids were electroporated into bacterial cells and selected with the encoded
946 antibiotics (carbenicillin, kanamycin). Plasmid DNA was obtained by Qiagen Maxiprep according
947 to manufacturer's protocol.

948

949 *Transposon Excision:* Inserted transposons were excised by treatment with either meganuclease I-
950 SceI or I-CeuI in CutSmart Buffer (NEB). Reactions were incubated at 37°C for 8 hours, with brief
951 mixing by inversion performed every 2 h. DNA was extracted by phenol-chloroform, precipitated
952 by MgCl₂/PEG-8000, and ethanol washed for the next stages.

953

954 *Chewback:* Substrate DNA was heated to 60°C for 3 min and immediately placed on ice to separate
955 DNA aggregates in preparation of chewback. Four standard chewback reactions were prepared,
956 each with a different chewback length (5, 10, 15, and 20 minutes). At the appropriate time, the

957 indicated reaction was removed from 37°C incubation and dNTPs were added. The reaction was
958 mixed and returned to 37°C to allow T4 DNA Polymerase to fill in recessed ends. After 11 minutes
959 of fill in, the reaction was halted and placed on ice. All chewback reactions were pooled and then
960 extracted with two phenol chloroform extractions. The DNA was desalted by running through
961 separate Sephacryl gel filtration columns (Microspin S-400 HR columns (GE Lifesciences)).

962

963 *End Repair:* DNA was pooled and blunt-ended by NEBNext End Repair Reaction Module (NEB),
964 incubating at 20°C for 30 minutes. DNA was extracted by phenol-chloroform, precipitated by
965 MgCl₂/PEG-8000, and ethanol washed for the next stages.

966

967 *Addition of 3'-dA overhang to backbone:* A 3'-dA overhang was added to the purified blunt-end
968 truncated linear pNL4-3 DNA with a 3'→5' exonuclease-deficient Klenow Fragment of E. coli
969 DNA Polymerase I (NEB). The reaction was incubated at 37°C for 1 hour, and then heat-
970 inactivated (70°C for 20 minutes). Treatment with Antarctic Phosphatase (NEB) per
971 manufacturer's protocol dephosphorylated the 5' ends (1 hour at 37°C, 5 minutes at 70°C to
972 deactivate). DNA was migrated on a 0.8% agarose gel and stained with SYBR Safe. All DNA
973 vectors greater than 8 kb were excised, recovered with β-agarase, precipitated with sodium acetate
974 and 2-propanol, and ethanol washed.

975

976 *Ligation of Barcode Cassettes and chewed vector:* 3'-dT-tailed barcode cassettes were ligated into
977 a 3'-dA-tailed vector and the DNA circularized using T4 DNA Ligase in a PEG-6000 containing
978 buffer (Quick Ligation Buffer, NEB). Ligation was performed at a 30:1 insert:vector molar ratio
979 at bench temperature (24°C) for 2 hours, then the reaction was halted by adding EDTA (pH 8.0)

980 and mixing. Next, Proteinase K (800 U/ml) (NEB) was added, the reaction mixed, then incubated
981 for 30 min at 37°C to cleave bound T4 DNA Ligase from the DNA.

982

983 *Sealing of nicks in hemiligated DNA:* Nicked DNA was sealed by sequential treatment with T4
984 Polynucleotide Kinase (T4 PNK) and *Taq* DNA Ligase. Hemiligated DNA was 5'-phosphorylated
985 with T4 PNK in T4 DNA Ligase Reaction Buffer (NEB) at 25°C for 30 minutes. Reactions were
986 purified with AMPure XP beads (Beckman-Coulter Genomics) and eluted with T4 DNA Ligase
987 Master Mix. The eluate was incubated at 37°C for 60 minutes to phosphorylate DNA at the nicked
988 sites. The nicks were then sealed by treatment with *Taq* DNA Ligase (NEB) in *Taq* DNA Ligase
989 Reaction Buffer at 75°C for 15 minutes. Ligated DNA was purified by AMPure XP beads and
990 eluted in TE.

991

992 *Library transformation and outgrowth:* The purified ligation was electroporated into
993 electrocompetent *E. coli* (DH10B) cells. Cells were allowed to recover in SOC (Thermo Fisher),
994 and then expanded for overnight growth in LB-Miller supplemented with carbenicillin. Finally,
995 Deletion Library Plasmid DNA was isolated from spun-down, harvested cultures by Qiagen
996 Maxiprep.

997

998

999 **Transfection of Viral Stocks:** Co-transfections were with an equal ratio of wild-type and deletion
1000 library plasmid. 293T cells were added to flasks at a ratio of 5e6 cells/mL in DMEM supplemented
1001 with 25mM HEPES. Wild-type and deletion library plasmids were diluted in unsupplemented
1002 DMEM (i.e., no serum or antibiotics added) to a concentration of 10 ng/mL total DNA and PEI

1003 was added to a concentration of 30 µg/mL in a volume ~10% of the total volume in the transfection
1004 well or dish (e.g., 200 µl for a 6-well plate with 2 mL media). The transfection mix was vortexed,
1005 incubated at bench temperature (24°C) for 15 minutes, then added to the 293T flasks. Media was
1006 replaced after an overnight incubation (16–20 hours). Virus was harvested at either 48 hours (HIV)
1007 or 72 hours (ZIKV) post-transfection by passing through 0.45 µm sterile filters (Millipore). HIV-
1008 1 stocks were prepared with pNL4-3 and the pNL4-3 deletion library. ZIKV viral stocks were
1009 prepared with pMR766(+) and one of the four MR-766 deletion libraries: pMR766(+) Δ S,
1010 pMR766(+) Δ L, pMR766(-) Δ S, or pMR766(-) Δ L.

1011

1012 **HIV High MOI Screen:**

1013 *Concentration of Virus:* Concentrated virus was prepared by ultracentrifugation (Beckman Coulter
1014 Optima XE-90, rotor SW 28) at 20,000 rpm through a 6% iodixanol gradient (Sigma Aldrich,
1015 D1556-250mL) for 1.5-2 hours at 4°C.

1016

1017 *Titration of Viral Stocks:* The concentrated HIV-1 stocks were titrated by infecting cultures of MT-
1018 4 with concentrated virus and scoring for HIV p24-producing cells at 24 hours post-infection.
1019 Virus was added to MT-4 cells in R10, mixed briefly, then incubated for 4 hours at 37°C. After 4
1020 hours, additional media was added, and the infection allowed to proceed for an additional 20 hours
1021 (a single-round of replication). At 24 hours post-infection, cultures were fixed with 20%
1022 formaldehyde (tousimis) and incubated for at least 1 hour at 4°C. After fixing, cells were
1023 permeabilized by treatment with 75% ice-cold methanol for 10 minutes, then stained with a
1024 phycoerythrin-labelled monoclonal antibody (KC57-RD1,BD) for 30 minutes before washing

1025 once in stain buffer. At least 50,000 live cells were counted by flow cytometry on a FACS Calibur
1026 DXP8. Gates were drawn based upon stained naive cell population. Analysis was done in FlowJo.

1027

1028 *High MOI passage scheme:* On day 0, 2×10^6 MT-4 cells were infected at a MOI of 5-20 with the
1029 prepared and titrated virus pool for 4 hours in a volume of 2 ml, then transferred to a T25 flask
1030 containing 10 ml of MT-4 cells at a concentration of 10^6 cells/ml. On day 2 (40 hours post infection
1031 (hpi)), the 12 ml of culture was transferred to a T175 flask containing 60 ml of MT-4 cells in R10
1032 at a concentration of 10^6 cells/ml. On day 3 (70-72 hpi), supernatant from the MT-4 was clarified
1033 by centrifugation and 0.45 μ m filtration, then concentrated by ultracentrifugation as described
1034 above. One cycle corresponds to 3 rounds of HIV-1 replication (completed on day 1, day 2, day
1035 3) and was repeated four times for a total of 12 passages (i.e. rounds of replication). The cycle was
1036 repeated a total of four times (12 passages / rounds of replication) with 3 biological replicates (K,
1037 L, M). Wild-type pNL4-3 controls were passaged alongside the deletion library, also in triplicate
1038 (A, B, C).

1039

1040 *Viral RNA Isolation:* Viral RNA was isolated from the concentrated virus pool at passage 0,
1041 passage 3, passage 6, passage 9, and passage 12 using a QIAmp Viral RNA Mini Kit (Qiagen) per
1042 the manufacturer's instructions with two exceptions: 1) carrier RNA was replaced with 5 of linear
1043 polyacrylamide (Sigma) per isolation; and 2) $5 \cdot 10^6$ copies of bacteriophage MS2 RNA (Roche)
1044 were spiked in per isolation. Total cellular RNA from 293T cells was isolated using Trizol (Life
1045 Technologies) from cell pellets obtained at the time of viral harvest. A poly(A) fraction,
1046 representing mRNA, was isolated by annealing total RNA to magnetic d(T)₂₅ beads to pull down
1047 polyadenylated transcripts (NEBNext Poly(A) mRNA magnetic isolation module).

1048

1049 *RT-qPCR Analysis:* Purified vRNA was reverse-transcribed with Superscript III (Thermo Fisher)
1050 and Random Primer Mix (New England Biolabs) for quantification by RT-qPCR with Fast SYBR
1051 Green Master Mix (Thermo Fisher). Barcode cassettes were quantified by oligos BC20v1-F and
1052 BC20v1-R. Total HIV RNA was estimated by primers targeting HIV *pol*, NL43pol-F and
1053 NL43pol-R. Samples were normalized for recovery by determining levels of MS2 RNA recovered
1054 by oligos MS2-F and MS2-R (sequences from (89)). Relative expression was calculated by
1055 traditional RT-qPCR methods (90). Oligos sequences can be found in Table S2.

1056

1057 **ZIKV High MOI Screen**

1058 *Concentration of Viral stocks:* Virus stocks were concentrated by ultrafiltration. Clarified
1059 supernatant was added to a 100 kDa MWCO filtration device in 20 aliquots. The device was spun
1060 at 1200×g for 20–30 min until the concentrate volume was less than 1 mL. The flowthrough
1061 fraction was removed and an additional supernatant added to the upper reservoir and the process
1062 repeated. Generally, clarified supernatant was concentrated 20–40X. Concentrated stocks were
1063 adjusted to 20% (v/v) FBS and 10 mM HEPES (to reduce loss in infectivity from freeze-thawing).

1064

1065 *Titration of Viral Stocks:* ZIKV stocks were titrated by plaque assay (91). On the day before
1066 infection, Vero cells were seeded in 6-well or 12-plates at approximate 50% confluency. On the
1067 day of infection (0 dpi), serial 10-fold dilutions of sample stocks were prepared by dilution in
1068 DMEM supplemented with 3% (v/v) heat-inactivated FBS. The media from each well of the
1069 infection plate was removed and replaced with serially-diluted virus. The plate was gently rocked
1070 and returned to the incubator for a period of 1 hour, with gently rocking applied every 15 minutes.

1071 After one hour of adsorption, the virus was removed and the cultures overlaid with a viscous
1072 solution of 1% (w/v) carboxymethylcellulose (Sigma #C4888) in DMEM-F12 (8% FBS, 1%
1073 pen/strep). Infection plates were returned to the incubator and left undisturbed for 5 days. At 5 dpi,
1074 the wells were with 20% formaldehyde and mixed gently for 1 hour. The supernatant was removed
1075 and the culture stained with a solution of 1% crystal violet in 20% ethanol for 15 minutes. Wells
1076 were de-stained by rinsing with dH₂O. Plaques were 1-2 mm in diameter and could be visualized
1077 as clear circular patches on the stained purple monolayer.

1078

1079 *High MOI passage scheme:* On day 0, Vero cells were infected at a MOI of 16–30 with a virus
1080 pool containing wild-type ZIKV and ZIKV deletion libraries. The inoculum was applied in a low
1081 volume in a 6-well plate for 1 hour, then removed. Supernatant was collected at 1, 2, and 3 dpi,
1082 corresponding to one passage. Virus from passage 1 was titrated by plaque assay and used to infect
1083 Vero cells for passage 2. The passage scheme was conducted with 2 biological replicates.

1084

1085 *Viral RNA Isolation:* ZIKV Viral RNA was isolated from the concentrated virus pool at 293T
1086 transfection, passage 1, and passage 2 per similar methods to the HIV screen.

1087

1088 *RT-qPCR Analysis:* Purified RNA was reverse-transcribed with MuLV-R (NEB) and Random
1089 Primer Mix (NEB) for quantification by RT-qPCR with SYBR Green Master Mix. Barcode
1090 cassettes were quantified by oligos BC20v2-F and BC20v2-R. Total ZIKV RNA was estimated by
1091 primers targeting the ZIKV capsid protein (ZIK-C), MR766-C-F and MR766-C-R. Samples were
1092 normalized for recovery by determining levels of MS2 RNA recovered by oligos MS2-F and MS2-

1093 R. Relative expression was calculated as done in the HIV-1 screen. Oligos sequences can be found
1094 in Table S2.

1095

1096 **NGS Analysis**

1097 *Genotyping of plasmid libraries:* Insertion and deletion plasmid libraries were prepared for paired-
1098 end sequencing on the Illumina HiSeq/MiSeq platforms by a Nextera XT Kit (Illumina) from 1 ng
1099 of each library. Transposon insertion and PCR enrichment were performed per the manufacturer's
1100 instructions, but the sublibraries were pooled and size-selected by running out on a 1.5% agarose
1101 gel, staining with SYBR Safe (Thermo Fisher), and excising a gel fragment corresponding to DNA
1102 of size range of 350–500 bp. DNA was purified from the gel slice using Qiagen Buffer QG, Buffer
1103 PE (Qiagen), and DCC-5 columns (Zymo Research). The sublibraries were pooled and sequenced
1104 on a single lane of a HiSeq4000 (Illumina), using 2×125 bp reads.

1105 Transposon insertion locations were computed by filtering for high-quality reads containing an
1106 exact match of either mosaic end sequence of TN5MK, then extracting flanking regions to build
1107 an insertion map. A lookup table matching deletion locus to barcode sequence was determined by:
1108 1) searching reads for the forward and reverse common barcode sequences and extracting the
1109 intermediate 20 bp; 2) assembling a list of barcode sequences; and 3) assigning flanking regions
1110 to each barcoded deletion using custom Python software.

1111

1112 *Sequencing of serial passage:* Illumina sequencing libraries were prepared by a modification of a
1113 method specified in (92) and detailed in Figure S5. Barcode cassettes were amplified using a
1114 minimum number of cycles (typically 12-18) to prevent overamplification (post log-phase PCR).
1115 Illumina adaptors were added by two rounds of PCR (5 cycles each), to add phasing adaptors,

1116 random barcodes, and multiplexing barcodes. Sublibraries were size-selected on 5% TBE
1117 polyacrylamide gels and pooled for sequencing. 20–30 sublibraries were sequenced on two lanes
1118 of a HiSeq4000 (Illumina) (spiked with 25% PhiX), using a single 1×50 b read at the Center for
1119 Advanced Technology at University of California, San Francisco. Barcodes were tallied using
1120 custom Python software and matched to deletion loci using the lookup table prepared previously
1121 to calculate deletion depth.

1122

1123 **Data availability**

1124 The data that support the findings of this study are available from the corresponding author upon
1125 reasonable request.

1126

1127 **Biological materials availability**

1128 All unique biological materials are available from the corresponding author.

1129

1130 **Code availability**

1131 Custom code is available upon request.

1132

1133 **Acknowledgements**

1134 We thank the Weinberger lab for discussions and suggestions. We thank Kathryn Claiborn for
1135 editing. The following reagents were obtained through the NIH AIDS Reagent Program, Division
1136 of AIDS, NIAID, NIH: MT-4 from Dr. Douglas Richman (cat# 120) and pNL4-3 molecular clone
1137 from Dr. Malcolm Martin (cat #114). This work was supported by the Bowes Distinguished
1138 Professorship, the Alfred P. Sloan Research Fellowship, the Pew Scholars in the Biomedical

1139 Sciences Program, the DARPA INTERCEPT program (D17AC00009), and the NIH Director's
1140 New Innovator (OD006677) and Pioneer Award (OD17181) programs.

1141

1142 **Author contributions**

1143 T.N. and L.S.W. conceived and designed the study. T.N., V.R.S, and C.E.T., designed and
1144 performed the experiments, and curated the data. J.J.G. and L.S.W. wrote the paper.

1145

1146 **Competing interests:**

1147 The authors declare that they have no competing interests

1148

1149 Supplementary information is included with this manuscript

1150